Published by top news
Posted on August 18, 2021
8 min readLast updated: February 16, 2026
Add as preferred source on Google
The global demand for stent graft balloon catheter will register a healthy expansion during 2017 to 2022. Revenues from the market are expected to surpass US$ 1,000 Mn by the end of 2022.
Usually utilized in bypass graft surgery as well as balloon angioplasty, stent graft balloon catheters prevent risks concerning occurrence of re-narrowing in patients undergoing angioplasty, and risks related to abrupt artery closure. Owing to these advantages offered by stent graft balloon catheters, their demand is witnessing a rise. A gradual evolution has been observed in the stent graft balloon catheter market, from the simple stents to modification of balloon stent catheters. Since recent past, there has been a surge in hospital admissions caused by increasing cases of atherosclerosis, and soaring prevalence of CAD – coronary artery disease globally. Numerous developments have been realized in technology of balloon catheters, along with the hike in healthcare expenditure. These factors are expected to augment growth of the market. In contrast, high prices of angioplasty procedures has become a problem for population across developing and underdeveloped economies. This might act as an impeding factor for the market growth.
To remain ‘ahead’ of your competitors, request a sample
https://www.factmr.com/connectus/sample?flag=S&rep_id=149
Growth of the global stent graft balloon catheter market has been highly favored by the advent of drug eluting balloons. In addition, shifting preferences towards using balloons with drug delivery, and helping to deliver medications at local sites, has deemed them to be effective substitutes for administering drugs intravenously. Various new products developed are being approved for treatment of vascular diseases. For instance – recently, the FDA has approved use of expandable balloon stent graft introduced by the W.L. Gore & Associates to treat peripheral artery disease. Moreover, technology advancements in the stent graft balloon catheters, coupled with increasing awareness about angioplasty, and sophisticated healthcare infrastructure in developed economies are further poised to drive the market growth in the near future.
For critical insights on this market, request for methodology here-
https://www.factmr.com/connectus/sample?flag=RM&rep_id=149
| Indication |
|
| End User |
|
| Raw Material |
|
Speak To Research Analyst For Detailed Insights:
https://www.factmr.com/connectus/sample?flag=AE&rep_id=149
Key players contributing to growth of the market
Meril Life Sciences Pvt. Ltd. Abbott Laboratories, Hexacath, Cardionovum GmbH, Jotech GmbH, MicroPort Scientific Corporation, Boston Scientific Corporation, Terumo Corporation, Cook Medical INC, B. Braun Melsungen AG, Cordis Corporation, and Medtronic Plc.
For More Insights
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
The global demand for stent graft balloon catheter will register a healthy expansion during 2017 to 2022. Revenues from the market are expected to surpass US$ 1,000 Mn by the end of 2022.
Usually utilized in bypass graft surgery as well as balloon angioplasty, stent graft balloon catheters prevent risks concerning occurrence of re-narrowing in patients undergoing angioplasty, and risks related to abrupt artery closure. Owing to these advantages offered by stent graft balloon catheters, their demand is witnessing a rise. A gradual evolution has been observed in the stent graft balloon catheter market, from the simple stents to modification of balloon stent catheters. Since recent past, there has been a surge in hospital admissions caused by increasing cases of atherosclerosis, and soaring prevalence of CAD – coronary artery disease globally. Numerous developments have been realized in technology of balloon catheters, along with the hike in healthcare expenditure. These factors are expected to augment growth of the market. In contrast, high prices of angioplasty procedures has become a problem for population across developing and underdeveloped economies. This might act as an impeding factor for the market growth.
To remain ‘ahead’ of your competitors, request a sample
https://www.factmr.com/connectus/sample?flag=S&rep_id=149
Growth of the global stent graft balloon catheter market has been highly favored by the advent of drug eluting balloons. In addition, shifting preferences towards using balloons with drug delivery, and helping to deliver medications at local sites, has deemed them to be effective substitutes for administering drugs intravenously. Various new products developed are being approved for treatment of vascular diseases. For instance – recently, the FDA has approved use of expandable balloon stent graft introduced by the W.L. Gore & Associates to treat peripheral artery disease. Moreover, technology advancements in the stent graft balloon catheters, coupled with increasing awareness about angioplasty, and sophisticated healthcare infrastructure in developed economies are further poised to drive the market growth in the near future.
For critical insights on this market, request for methodology here-
https://www.factmr.com/connectus/sample?flag=RM&rep_id=149
| Indication |
|
| End User |
|
| Raw Material |
|
Speak To Research Analyst For Detailed Insights:
https://www.factmr.com/connectus/sample?flag=AE&rep_id=149
Key players contributing to growth of the market
Meril Life Sciences Pvt. Ltd. Abbott Laboratories, Hexacath, Cardionovum GmbH, Jotech GmbH, MicroPort Scientific Corporation, Boston Scientific Corporation, Terumo Corporation, Cook Medical INC, B. Braun Melsungen AG, Cordis Corporation, and Medtronic Plc.
For More Insights
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
Coronary artery disease (CAD) is a condition characterized by the narrowing of the coronary arteries, which supply blood to the heart muscle, often leading to heart problems.
Angioplasty is a minimally invasive procedure used to open blocked or narrowed blood vessels, often using a balloon catheter to restore blood flow.
Explore more articles in the Research Reports category
